Challenges in the management of oligometastatic lung cancer

<bold>Introduction:</bold> The challenge for an oligometastatic lung cancer is to planify a curative therapeutic regimen for the tumor and its metastasis. The aim of this study was analyze the profile of oligometastatic lung cancers, and to study the impact of metastases and their management on local cancer treatment <bold>Materials and methods:</bold> This is a retrospective study conducted in the pneumology department Pavilion 4 during the period from 2021 to 2023. We included patients that have been followed up for confirmed stage 4 oligometastatic bronchopulmonary cancer. An oligometastatic state was defined as a number of metastases between 1 to 3 <bold>Resultas:</bold> A total of 40 patients were included with a mean age of 62.2 ±10 years, 97.5% of whom were men. All patients were smokers with an average consumption of 51.85 (±32) pack-years. Sixty percent were in stage 4A versus 40% in stage 4B. The adenocarcinoma was the most common histological type (67.5%). The metastases were discovered before the diagnosis of the primary tumor in 27.5% of cases. The cancer was mono metastatic in 57.5% of cases, the most frequent site was cerebral 15%. In cases of multiple metastases, the average number was 2.58 metastasis, the pleural site was dominant 20% of the time. Thirty-seven percent of metastases were symptomatic. 27.5% of patients required preparation prior to initiation of antimitotic therapy (corticosteroids, drainage, supportive and nutritive care). The response to Palliative chemotherapy was as follows: 17.5% stability, 17.5% partial response, 5% total response and 47.5% progression. A curative therapeutic regimen was performed in 7.5% of patients. <bold>Conclusion:</bold> Using a palliative therapeutic regimen for an oligometastatic lung cancer leads to a poor prognosis